BioVie (BIVI) Competitors $1.87 -0.01 (-0.53%) Closing price 04:00 PM EasternExtended Trading$1.90 +0.02 (+1.34%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BIVI vs. INMB, BRNS, ATNM, FGEN, TPST, VRCA, LTRN, PEPG, NBRV, and RNXTShould you be buying BioVie stock or one of its competitors? The main competitors of BioVie include INmune Bio (INMB), Barinthus Biotherapeutics (BRNS), Actinium Pharmaceuticals (ATNM), FibroGen (FGEN), Tempest Therapeutics (TPST), Verrica Pharmaceuticals (VRCA), Lantern Pharma (LTRN), PepGen (PEPG), Nabriva Therapeutics (NBRV), and RenovoRx (RNXT). These companies are all part of the "pharmaceutical products" industry. BioVie vs. Its Competitors INmune Bio Barinthus Biotherapeutics Actinium Pharmaceuticals FibroGen Tempest Therapeutics Verrica Pharmaceuticals Lantern Pharma PepGen Nabriva Therapeutics RenovoRx INmune Bio (NASDAQ:INMB) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation. Do analysts rate INMB or BIVI? INmune Bio presently has a consensus target price of $18.40, indicating a potential upside of 815.42%. Given INmune Bio's higher probable upside, equities analysts plainly believe INmune Bio is more favorable than BioVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57BioVie 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Is INMB or BIVI more profitable? BioVie's return on equity of -89.02% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets INmune BioN/A -120.62% -92.94% BioVie N/A -89.02%-75.32% Do institutionals and insiders have more ownership in INMB or BIVI? 12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 35.7% of INmune Bio shares are owned by insiders. Comparatively, 2.4% of BioVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, INMB or BIVI? BioVie has lower revenue, but higher earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioINmune Bio$10K5,342.58-$42.08M-$2.48-0.81BioVieN/AN/A-$17.54M-$79.10-0.02 Does the media refer more to INMB or BIVI? In the previous week, INmune Bio had 1 more articles in the media than BioVie. MarketBeat recorded 2 mentions for INmune Bio and 1 mentions for BioVie. BioVie's average media sentiment score of 1.91 beat INmune Bio's score of 0.64 indicating that BioVie is being referred to more favorably in the news media. Company Overall Sentiment INmune Bio Positive BioVie Very Positive Which has more risk & volatility, INMB or BIVI? INmune Bio has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, BioVie has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. SummaryINmune Bio beats BioVie on 8 of the 14 factors compared between the two stocks. Get BioVie News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIVI vs. The Competition Export to ExcelMetricBioVieMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.16M$2.59B$5.86B$10.15BDividend YieldN/A56.51%5.68%4.59%P/E Ratio-0.0223.5374.5225.93Price / SalesN/A697.48539.62123.65Price / CashN/A171.1637.5660.44Price / Book0.195.3712.166.29Net Income-$17.54M$32.95M$3.28B$270.77M7 Day Performance7.47%1.31%0.98%3.36%1 Month Performance11.98%8.31%7.20%6.41%1 Year Performance-94.10%0.29%63.06%28.26% BioVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIVIBioVie0.6806 of 5 stars$1.87-0.5%N/A-93.5%$14.16MN/A-0.0210Positive NewsGap UpINMBINmune Bio2.9762 of 5 stars$1.81-7.2%$18.40+916.6%-68.4%$51.84M$10K-0.7310Short Interest ↓BRNSBarinthus Biotherapeutics2.9869 of 5 stars$1.22-2.0%$3.00+146.9%-4.6%$50.49M$14.97M-0.70107Positive NewsGap UpATNMActinium Pharmaceuticals3.062 of 5 stars$1.60+1.3%$4.50+181.3%-13.8%$49.91MN/A-1.1530Positive NewsShort Interest ↑FGENFibroGen4.5114 of 5 stars$11.16-7.8%$43.00+285.3%+25.4%$48.93M$29.62M-29.37570News CoverageTPSTTempest Therapeutics2.4519 of 5 stars$10.85-1.3%$30.00+176.5%-40.3%$48.80MN/A-0.7420Positive NewsVRCAVerrica Pharmaceuticals4.0829 of 5 stars$5.06-1.0%$80.00+1,481.0%-74.4%$48.22M$7.57M-0.6140LTRNLantern Pharma2.5962 of 5 stars$4.06-5.8%$25.00+515.8%+5.6%$46.54MN/A-2.2820Positive NewsPEPGPepGen2.8258 of 5 stars$1.49+6.4%$7.67+414.5%-85.0%$45.92MN/A-0.5030Analyst ForecastGap UpNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070RNXTRenovoRx2.3401 of 5 stars$1.14-8.1%$7.50+557.9%+18.0%$45.44M$40K-3.006News CoverageShort Interest ↑Gap Up Related Companies and Tools Related Companies INmune Bio Competitors Barinthus Biotherapeutics Competitors Actinium Pharmaceuticals Competitors FibroGen Competitors Tempest Therapeutics Competitors Verrica Pharmaceuticals Competitors Lantern Pharma Competitors PepGen Competitors Nabriva Therapeutics Competitors RenovoRx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIVI) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredChina’s message to TrumpDid China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of mi...Porter & Company | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIVI Stock Alerts